Health Condition 1: null- moderate depression
Conditions
Interventions
Intervention1: desvenlafaxine: Desvenlafaxine 50mg -100mg /day for 8 weeks ,it is a SNRI used in treatment of depression.
Control Intervention1: Escitalopram: Escitalopram 10mg -20mg/day for 8weeks,it
Sponsors
Moulya Nagraj
Eligibility
Inclusion criteria
Inclusion criteria: • Subjects of either gender aged between 18-65 years. • Subjects with first episode or recurrent episode of depression according to (ICD-10) with baseline score >18 and • Willingness to give written informed consent and available for follow up.
Exclusion criteria
Exclusion criteria: • Atypical depression • Postpartum depression • Pregnant women, breast feeding and women planning to conceive. • Subjects with severe depression requiring ECT and with high risk of suicidal tendency. • Co-morbid psychiatric illnesses • Previous history of epilepsy and sexual dysfunction • Serious or uncontrolled medical illness like glaucoma, hypertension, diabetes mellitus, hyperlipidemia, myocardial infarction, hepatic and renal impairment. • Depression secondary to medical illnesses, post traumatic depression. • Known history of allergy to both the study medications. • Participation in any other research study in recent past
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| reduction of MADRS score to 12 or by 50% from baseline scores and QoL is measured using 12-item short form of the Medical Outcomes Study questionnaire (SF-12)Timepoint: baseline, 4week, 8 week, follow up | — |
Secondary
| Measure | Time frame |
|---|---|
| Remission of scores by 50%Timepoint: baseline,4 week, 8 week, follow up. | — |
Countries
India
Contacts
Public ContactDr Moulya Nagraj
Kempegowda Institute of Medical Sciences
Outcome results
None listed